Financials
- Financial year
- 2025
- Total assets
- €160,632
- Profit
- €20,367
- Solvency
- 28.7%
LIMACOM PHARMA
ActiveSummary
LIMACOM PHARMA has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,127 and a net result of €20,367. Its solvency ranks better than 41% of 13,595 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€160,632total assets 2025
- Equity
- €46,127
- Profit
- €20,367
Turnover not published (micro format)
Structure
- Board
- 4 members
Accounts filed 31 days late
Why 66raises riskFounded in 2025Latest accounts 31 days late; 1 of the last 3 lateSize: total assets €160,632lowers riskLiquidity: current ratio 1.58, cash €33,357Show the evidence
Checked score
Score 2025
66
/ 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 53% of its sector peers (NACE 46, micro)
Financial strength
Strong
Solvency
54
equity 28.7% of total assets
Liquidity
43
short-term debt 63.1% · cash 20.8%
Profitability
85
return on assets 12.7%
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
02-2026: 1.6%
03-2026: 1.6%● unchanged vs 02-2026
04-2026: 1.7%▲ +0.1 percentage points vs 03-2026
05-2026: 2.0%▲ +0.3 percentage points vs 04-2026
06-2026: 2.1%▲ +0.1 percentage points vs 05-2026
07-2026: 2.4%▲ +0.3 percentage points vs 06-2026
08-2026: 2.6%▲ +0.2 percentage points vs 07-2026highest value
09-2026: 1.1%▼ -1.5 percentage points vs 08-2026lowest value
10-2026: 1.1%● unchanged vs 09-2026
Credit of up to €3,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.58, above the usual 1.5; short-term debt: 63.1% and cash: 20.8% of total assets), but 71.3% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 39% on solvency, 41% on liquidity and 79% on profitability.
The bankruptcy probability was computed on 21-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 1 filingDeviation from the deadline
2025
31 days late
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · micro…
- Resignation: John Willems (director)Appointment: LIMACOM NV (director) ·…
- IncorporationAppointments: WILLEMS John, WILLEMS Isabelle…
Key points
By topic
Board & ownership
- Board
- 4 members
- LIMACOM NVDirector
- John WillemsDirector
- WILLEMS IsabelleDirector
- WILLEMS YvesDirector
Network & group
- Mergers and asset contributions
- 1
Timeline
- Events
- 3
- Since
- 2025
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Founded
- 15-01-2025
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 27
- Who signs
- Each director alone
- Annual meeting
- 1 June at 15:00
- Purpose
- “De vennootschap zal zowel voor eigen rekening of voor rekening van derden de productie…” (deed in Dutch)
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.